- Home
- GSIW vs CRVO Comparison
GSIW vs CRVO Comparison
Compare GSIW & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSIW | CRVO |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 35.9M |
| IPO Year | 2022 | 2011 |
Fundamental Metrics
Financial Performance| Metric | GSIW | CRVO |
|---|---|---|
| Price | $31.67 | $3.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 1.7K | ★ 50.2K |
| Earning Date | 08-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,006,510.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.05 | $2.82 |
| 52 Week High | $36.90 | $13.13 |
Technical Indicators
Market Signals| Indicator | GSIW | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.67 | 35.41 |
| Support Level | $0.11 | N/A |
| Resistance Level | $32.25 | $4.27 |
| Average True Range (ATR) | 1.62 | 0.25 |
| MACD | -0.59 | -0.06 |
| Stochastic Oscillator | 45.31 | 21.75 |
Price Performance
Historical ComparisonAbout GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.